NCT01224626View on ClinicalTrials.gov

Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)

CompletedOBSERVATIONAL
Enrollment

41

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Vancomycin Resistance Enterococcus Faecium
Interventions
DRUG

Zyvox (linezolid)

Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01224626 - Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE) | Biotech Hunter | Biotech Hunter